GCC Nurse Pulmonology Guide

📊 Spirometry Interpretation

Spirometry measures airflow and lung volumes. Key parameters:

Parameter	Definition	Normal
FVC	Forced Vital Capacity — total air exhaled forcefully	≥80% predicted
FEV1	Volume exhaled in first second	≥80% predicted
FEV1/FVC	Tiffeneau ratio — key for obstruction vs restriction	≥0.70
FEF 25–75%	Mid-expiratory flow — small airways marker	≥65% predicted

Pattern Recognition

Obstructive Pattern
FEV1/FVC < 0.70
FEV1 reduced, FVC may be normal or low
COPD, asthma, bronchiectasis

Restrictive Pattern
FEV1/FVC normal (≥0.70)
FVC reduced (<80%)
IPF, obesity, pleural disease, neuromuscular

Mixed Pattern: FEV1/FVC <0.70 AND FVC <80% — consider COPD + obesity or bronchiectasis + fibrosis

💉 Reversibility Test (Bronchodilator Response)

Salbutamol 400mcg via spacer (or 200–400mcg nebulised), repeat spirometry at 15–20 minutes.

Significant reversibility: FEV1 increases by ≥200 mL AND ≥12% from baseline

Significant reversibility suggests asthma (or asthma-COPD overlap)
COPD may show partial reversibility — does not exclude diagnosis
Fixed obstruction (minimal reversibility) typical of COPD
Complete normalisation of spirometry suggests asthma

💥 DLCO (Diffusion Capacity)

Measures how well CO transfers from alveoli to blood — reflects alveolar–capillary membrane integrity.

Condition	DLCO	Reason
Emphysema (COPD)	Reduced	Alveolar destruction, loss of surface area
Pulmonary Fibrosis (IPF)	Reduced	Thickened alveolar membrane
Pulmonary Hypertension	Reduced	Vascular obliteration
Polycythaemia	Increased	More haemoglobin available
Asthma (stable)	Normal/Increased	Airflow preserved
Anaemia	Reduced	Corrected for Hb in modern labs

DLCO <40% predicted = severe impairment; DLCO <60% in IPF = consider supplemental O2 on exertion

🏃 6-Minute Walk Test (6MWT)

Methodology

30-metre flat corridor, no obstacles
Patient wears comfortable shoes; standardise instructions
Baseline SpO2, HR, BP, Borg dyspnoea scale (0–10)
Walk at own pace for 6 minutes — encourage every 30 sec: "You're doing well, keep going"
Record distance walked, SpO2 nadir, Borg score, reason for stopping
Do NOT walk with the patient — follow 1 metre behind

Clinical Significance

Normal adults: 400–700m depending on age/sex
Desaturation >4% or SpO2 <88% during test = ambulatory O2 indication
Minimal clinically important difference (MCID): 25–35m
Used in IPF, pulmonary hypertension, COPD for prognosis and treatment response

📃 Peak Flow Monitoring

Peak Expiratory Flow Rate (PEFR) — measured in L/min. Portable, quick, bedside.

Personal Best

Establish over 2 weeks when asthma is well-controlled. All zones calculated from this value.

GREEN ≥80%

AMBER 50–79%

RED <50%

Zone	Action
GREEN ≥80%	Good control. Continue preventer. No rescue needed
AMBER 50–79%	Caution. Increase reliever. Consider oral steroid. Review trigger
RED <50%	Medical emergency. High-dose bronchodilator, O2, call doctor immediately

Technique Checklist

Reset cursor to zero before each blow
Standing (or sitting upright) position
Deep breath in, seal lips tightly around mouthpiece
Blow out as hard and fast as possible (not sustained)
Record the best of 3 attempts

📄 GOLD Classification (2023 Update)

GOLD now classifies by symptoms + exacerbation history (ABE), not FEV1 alone. FEV1% still used for severity grading.

GOLD Group	Symptoms	Exacerbations	First Choice
Group A	Low (mMRC 0–1, CAT <10)	0–1 (not hospitalised)	Bronchodilator (any)
Group B	High (mMRC ≥2, CAT ≥10)	0–1 (not hospitalised)	LABA + LAMA
Group E	Any	≥2 or ≥1 hospitalisation	LABA + LAMA (± ICS if eos ≥300)

Airflow Limitation Severity (FEV1% predicted)

GOLD 1: FEV1 ≥80% (Mild) GOLD 2: FEV1 50–79% (Moderate) GOLD 3: FEV1 30–49% (Severe) GOLD 4: FEV1 <30% (Very Severe)

Blood eosinophils ≥300 cells/µL → add ICS to LABA+LAMA (reduces exacerbation risk). Eos <100 → ICS not recommended (pneumonia risk).

💊 Inhaler Device Selection

Device	Technique Key Points	Best For
MDI + Spacer	Shake well, actuate into spacer, slow deep breath, 5-sec hold	Elderly, poor coordination, acute attack
DPI (e.g. Turbohaler, Ellipta)	Fast forceful inhalation, no spacer needed, keep dry	Adequate inspiratory flow (>30 L/min)
SMI (Respimat)	Slow steady inhalation, 5-sec hold, no shaking	Patients with weak inspiratory flow
Nebuliser	Tidal breathing, 6–8 min, clean after each use	Acute exacerbations, severe disease

Check technique at every visit. Up to 70% of patients have poor inhaler technique — a leading cause of poor control.

💉 Drug Classes: LAMA / LABA / ICS

LAMA (Long-Acting Muscarinic Antagonist)

Tiotropium (Spiriva), umeclidinium, aclidinium, glycopyrronium
Once daily; reduces exacerbations and hyperinflation
Avoid if narrow-angle glaucoma (use MDI + spacer)
Side effects: dry mouth, urinary retention

LABA (Long-Acting Beta2 Agonist)

Salmeterol, formoterol (twice daily); indacaterol, vilanterol (once daily)
Bronchodilation via beta-2 receptor relaxation
Not for acute relief in COPD — use SABA PRN
Combined LABA+LAMA: Anoro (umeclidinium/vilanterol)

ICS (Inhaled Corticosteroid)

Fluticasone, budesonide, beclomethasone — reduce airway inflammation
In COPD: only add if eos ≥300 or frequent exacerbations despite dual BD
Rinse mouth after use (oral candidiasis prevention)
Triple therapy: LABA + LAMA + ICS (e.g. Trelegy Ellipta)

🚨 Acute COPD Exacerbation Management

Definition: Acute worsening of respiratory symptoms beyond normal day-to-day variation requiring change in medication.

Step-by-Step Management

Controlled O2: Target SpO2 88–92%. Use 24% Venturi mask. Avoid uncontrolled high-flow O2 — risk of hypercapnic respiratory failure
SABA: Salbutamol 2.5mg nebulised q20min initially, then q4h
SAMA: Ipratropium 500mcg nebulised q6–8h (combine with SABA)
Oral Prednisolone: 30mg daily for 5 days (not longer — no extra benefit)
Antibiotics — Anthonisen Criteria (need ≥2 of 3):

Anthonisen Criteria: (1) Increased purulence of sputum (2) Increased sputum volume (3) Increased dyspnoea
If ≥2 present → antibiotic (amoxicillin/doxycycline/clarithromycin). Suspect Pseudomonas if repeated hospitalisations or bronchiectasis → use ciprofloxacin.

Investigations

ABG: assess pH, PaCO2, PaO2 — guide NIV decision
CXR: exclude pneumonia, pneumothorax
ECG: cor pulmonale, arrhythmias
FBC, CRP, U&E, sputum C&S
Theophylline level if on theophylline

💀 NIV for Type 2 Respiratory Failure

Type 2 RF: PaCO2 >6.0 kPa + acidosis. pH guides urgency of NIV.

ABG pH	Action
pH ≥7.35	Medical management, monitor closely with repeat ABG
pH 7.25–7.34	Trial NIV (BiPAP) — target correction within 1–4 hours; repeat ABG at 1h
pH <7.25	Urgent NIV + senior/ICU review; consider intubation if no improvement

NIV Settings (Starting Points)

IPAP 12–16 cmH2O; EPAP 4–6 cmH2O (titrate to response)
Backup rate 12–14 bpm; FiO2 to target SpO2 88–92%
Check mask fit — key cause of failure is air leak
Aim for at least 4 hours continuous use initially
Reassess with ABG at 1 hour

Contraindications: vomiting, unable to protect airway, facial trauma, haemodynamic instability (relative), recent upper GI surgery

👑 Pulmonary Rehabilitation

Minimum 8 weeks (16+ supervised sessions) — proven to reduce hospitalisation and mortality
Includes: aerobic exercise (walking/cycling), strength training, education, nutritional support, psychosocial support
Indicated after any hospitalisation for exacerbation (within 4 weeks = higher benefit)
MRC dyspnoea scale 3–5 = key referral group
Not indicated during active exacerbation
Nurse role: motivate adherence, monitor SpO2 during exercise, provide inhaler education

📊 COPD Exacerbation Risk Stratifier (GOLD A/B/E)

FEV1 % predicted

Exacerbations in last 12 months

CAT Score (0–40)

Blood Eosinophils (cells/µL)

🌡 GINA Treatment Steps

GINA 2023 recommends ICS-formoterol as preferred reliever at all steps (anti-inflammatory reliever therapy — MART).

Step	Preferred Controller	Reliever
Step 1	None or low-dose ICS as needed	Low-dose ICS-formoterol PRN
Step 2	Low-dose ICS daily	ICS-formoterol PRN or SABA
Step 3	Low-dose ICS-LABA	ICS-formoterol PRN
Step 4	Medium/high ICS-LABA	ICS-formoterol PRN; consider LAMA add-on
Step 5	High ICS-LABA + LAMA ± biologic	ICS-formoterol PRN

Step Up if uncontrolled for 1–3 months. Step Down if well-controlled for 3 months to find minimum effective dose.

💊 Add-On Therapies (Step 4–5)

LAMA (Tiotropium 2.5mcg SMI)

Approved for asthma ≥ 6 years at Step 4–5
Reduces exacerbations, improves lung function

Biologic Therapies

Drug	Target	Phenotype
Omalizumab	Anti-IgE	Allergic asthma, IgE elevated, sensitised allergen
Mepolizumab, Reslizumab	Anti-IL-5	Eosinophilic asthma (eos ≥300)
Benralizumab	Anti-IL-5Rα	Severe eosinophilic asthma
Dupilumab	Anti-IL-4/IL-13	Type 2 asthma, eczema, chronic rhinosinusitis
Tezepelumab	Anti-TSLP	Broad phenotype — even non-eosinophilic

Biologic criteria: uncontrolled severe asthma despite Step 4–5 optimised therapy, no smoking (or ex-smoker), good adherence and inhaler technique confirmed

📝 Spacer Technique & Cleaning

Technique (for MDI + Spacer)

Shake MDI well (10 shakes); insert into spacer
Breathe out gently (not into spacer)
Seal lips firmly around mouthpiece
Press MDI once; breathe in slowly and deeply (3–5 seconds)
Hold breath for 5–10 seconds
Wait 30 seconds before second puff
Replace cap on MDI; rinse mouth after ICS

Cleaning Spacer

Disassemble; wash in warm soapy water monthly (or weekly if used daily)
Do NOT rinse — leave to air dry (static charge reduced)
Replace spacer every 6–12 months or when visibly damaged
Plastic spacers: prime with 2 actuations into spacer before first use

📋 Written Asthma Action Plan

All asthma patients should have a personalised written plan based on symptoms OR peak flow.

GREEN: Well

AMBER: Caution

RED: EMERGENCY

Zone	Indicators	Action
GREEN	PEFR ≥80%, no symptoms at night, can exercise normally	Continue preventer, reliever not needed
AMBER	PEFR 50–79%, waking at night, using reliever >2×/week	Increase ICS-formoterol, add oral prednisolone if not improving
RED	PEFR <50%, unable to complete sentences, SpO2 <92%	Call emergency services, high-flow O2, nebulised salbutamol

🚨 Acute Severe & Life-Threatening Asthma

Acute Severe Asthma (ANY ONE of):
• PEFR 33–50% of best/predicted
• Cannot complete sentences in one breath
• Respiratory rate >25/min
• Heart rate >110/min
• SpO2 <92%

Life-Threatening Features (ANY ONE):
• PEFR <33% best/predicted
• Silent chest (no wheeze — airflow almost absent)
• SpO2 <92% despite O2
• PaCO2 normal/raised (fatigue)
• Cyanosis, bradycardia, hypotension
• Exhaustion, confusion, coma

Emergency Management

Sit upright; high-flow O2 15L/min via non-rebreathe mask; target SpO2 94–98%
Salbutamol 5mg nebulised continuously (or back-to-back)
Ipratropium 0.5mg nebulised q20min for 1 hour
Oral/IV prednisolone 40–50mg (or IV hydrocortisone 100mg)
Magnesium sulphate 2g IV over 20 min (life-threatening / no response to initial Rx)
ABG if SpO2 <92% or deteriorating — rising PaCO2 = impending respiratory arrest
ITU/anaesthetic review if PaCO2 rising, exhaustion, confusion, silent chest

💧 Pleural Effusion: Transudate vs Exudate

Use Light's Criteria — if ANY ONE of the three criteria met, it is an exudate (sensitivity 98%, specificity 83%).

Light's Criteria (exudate if ≥1 positive):
1. Pleural fluid protein / serum protein > 0.5
2. Pleural fluid LDH / serum LDH > 0.6
3. Pleural fluid LDH > 2/3 of upper limit of normal serum LDH

Common Transudate Causes

Heart failure (most common)
Hepatic cirrhosis / hypoalbuminaemia
Nephrotic syndrome
Hypothyroidism
Constrictive pericarditis

Common Exudate Causes

Malignancy (lung, breast, mesothelioma)
Parapneumonic / empyema
TB pleuritis
Pulmonary embolism
Rheumatoid / lupus

Note: If patient on diuretics, serum albumin gradient >12 g/L may reclassify borderline Light's exudate as transudate.

💊 Diagnostic Thoracocentesis

Pre-procedure

Confirm effusion with USS (real-time guided = gold standard for safety)
Check INR <1.5, platelets >50, no anticoagulation (or pause it)
Consent, explain procedure, position patient (seated, leaning forward on pillow)

Samples to Send

Sample	Container	Purpose
Protein & LDH	Plain tube	Light's criteria
pH	Heparinised syringe (ABG)	pH <7.2 = empyema/complex parapneumonic → drain
Glucose	Fluoride tube	Low in infection, malignancy, RA
Cytology	Large-volume plain tube (50–60mL)	Malignant cells — multiple samples improve yield
MC&S + AFB	Sterile universal container	Bacterial, fungal, TB cultures
Cholesterol, TG	Plain tube	If chylothorax suspected

Send paired serum samples at the same time: protein, LDH, glucose, albumin

💋 Therapeutic Thoracocentesis

For symptomatic relief of dyspnoea from large effusion
Maximum drain per session: 1.5 litres — exceeding this risks re-expansion pulmonary oedema
Stop if: patient develops cough, chest discomfort, or haemodynamic change
Monitor SpO2 and HR throughout procedure
Post-procedure CXR to exclude pneumothorax
Recurrent malignant effusion → consider indwelling pleural catheter (IPC) or pleurodesis

Re-expansion pulmonary oedema: cough, hypoxia, frothy sputum within hours of draining. Manage with O2, diuretics; rarely needs intubation.

🌄 Pneumothorax Types

Type	Definition	Management Principle
Primary SP	No underlying lung disease; young, tall, thin	Conservative if <2cm; aspirate if ≥2cm; chest drain if failing
Secondary SP	Underlying lung disease (COPD, asthma, CF)	All need admission; drain if ≥1cm or symptomatic
Tension	One-way valve; mediastinal shift; haemodynamic collapse	Immediate needle decompression 2nd ICS MCL, then drain

Tension Pneumothorax Signs: Tracheal deviation away, absent breath sounds, raised JVP, hypotension, tachycardia. Do NOT wait for CXR — clinical diagnosis!

💉 Pleurodesis Nursing Care

Pleurodesis creates pleural symphysis to prevent fluid/air re-accumulation. Talc is most effective agent.

Pre-procedure

Ensure lung is fully expanded on CXR before proceeding
Pre-medicate: IV morphine 2–5mg + IV midazolam 1–2mg (procedure is painful)
Consider intercostal nerve block with 0.25% bupivacaine

Nursing Management Post-Pleurodesis

Clamp chest drain for 1 hour post-talc instillation
Position changes every 15 min for first 2 hours to distribute talc
Monitor: pain, temperature (low-grade fever common), SpO2, respiratory rate
Analgesia: regular paracetamol + PRN opioid; NSAIDs may reduce pleurodesis success — avoid
Monitor drain output: drain removed when <150mL/24h and lung remains expanded
CXR before drain removal

Acute Lung Injury rare but serious complication of talc pleurodesis — monitor for increasing O2 requirements within 24–72h

🔋 Idiopathic Pulmonary Fibrosis (IPF)

Progressive fibrosing interstitial lung disease — median survival 3–5 years without treatment.

Diagnosis

HRCT: basal, subpleural honeycombing ± traction bronchiectasis (UIP pattern)
Progressive decline in FVC (≥10% in 12 months = poor prognosis)
Restrictive pattern on PFTs; reduced DLCO
Clubbing in 50%; fine Velcro crackles at bases
Surgical lung biopsy if HRCT atypical

Management

Pirfenidone (Esbriet) — anti-fibrotic, anti-inflammatory
Nintedanib (Ofev) — tyrosine kinase inhibitor, slows decline
Both reduce FVC decline ~50% vs placebo
Home O2 if resting SpO2 <88% or desaturation on exertion
Pulmonary rehabilitation; advance care planning
Lung transplant evaluation in eligible patients

Nintedanib: main side effects — diarrhoea, nausea. Pirfenidone: photosensitivity (advise sunscreen), rash, GI upset. Monitor LFTs for both.

👀 Sarcoidosis

Systemic granulomatous disease of unknown aetiology. Peak age 20–40. Common in Middle Eastern and South Asian populations.

Pulmonary Staging (Scadding)

Stage	Finding
0	Normal CXR
I	Bilateral hilar lymphadenopathy (BHL)
II	BHL + pulmonary infiltrates
III	Pulmonary infiltrates alone
IV	Fibrosis

Extra-Pulmonary Features

Eyes: anterior uveitis (commonest) — urgent ophthalmology
Skin: erythema nodosum, lupus pernio
Cardiac: heart block, VT — 24h Holter
Neurosarcoid: cranial nerve palsies (VII most common)
Hypercalcaemia (granuloma → 1,25-OH Vit D)
Elevated ACE (not diagnostic but tracks activity)

Treatment

Stage I: often resolves spontaneously — observe
Symptomatic / worsening / extrapulmonary: oral prednisolone 20–40mg daily
Taper over 6–12 months; methotrexate as steroid-sparing agent

❤️ Pulmonary Hypertension

Definition: mean PAP (mPAP) > 20 mmHg at rest on right heart catheterisation (RHC). RHC is the gold standard investigation.

WHO Groups

Group	Cause
1	Pulmonary arterial hypertension (PAH) — idiopathic, heritable, drug-induced, connective tissue
2	Left heart disease (most common)
3	Lung disease / hypoxia (COPD, IPF)
4	Chronic thromboembolic PH (CTEPH)
5	Unclear / multifactorial

WHO Functional Class

FC I: No limitation FC II: Slight limitation with ordinary activity FC III: Marked limitation — comfortable at rest FC IV: Unable to carry on any activity; symptoms at rest

Vasodilator Therapies (Group 1 PAH)

Drug Class	Example	Route	Notes
ERA	Bosentan, ambrisentan, macitentan	Oral	LFTs monthly; teratogenic — contraception essential
PDE-5i	Sildenafil, tadalafil	Oral	Avoid with nitrates; headache, flushing
Prostacyclin	Epoprostenol	IV continuous	Central line; do NOT stop abruptly — rebound death risk
Prostacyclin (inhaled)	Iloprost, treprostinil	Inhaled/SC	6–9 inhalations per day
sGC stimulator	Riociguat	Oral	Also approved for CTEPH

Epoprostenol infusion failure = immediate life threat. Have backup pump and emergency protocol in place. Never interrupt infusion.

🌔 Bronchiectasis

Permanent bronchial dilatation from recurrent infection/inflammation. CT chest (HRCT) confirms diagnosis.

Airway Clearance Techniques

Active Cycle of Breathing (ACBT): Breathing control → Thoracic expansion exercises → Forced expiration technique (FET/huff)
Postural drainage: position affected lobes uppermost
Oscillating PEP devices (Acapella, Flutter)
Minimum twice daily; increase during exacerbations
Physiotherapist to teach and supervise initially

Infection Surveillance

Sputum culture q3 months when stable (track organisms)
H. influenzae most common; Pseudomonas = poor prognosis marker
First Pseudomonas isolation → eradication protocol (ciprofloxacin 750mg BD 2 weeks)
Exacerbation: increased sputum, purulence, dyspnoea → antibiotic guided by culture

Azithromycin Prophylaxis

Azithromycin 250–500mg 3×/week — reduces exacerbation frequency in patients with ≥3 exacerbations/year. Check ECG (QTc prolongation), audiology, sputum for MAC before starting. Annual review.

🌞 GCC-Specific Asthma Triggers

The Gulf region has several unique asthma triggers that nurses must understand and educate patients about:

Environmental Triggers

Sandstorms (Haboob): PM10 particles spike 10–50x normal. Advise patients to stay indoors, wear N95 masks outdoors, avoid outdoor exercise 48h post-storm
Desert dust: Year-round elevated PM2.5 from dust events → chronic airway inflammation. Track Air Quality Index (AQI)
High temperatures (up to 50°C): Direct heat trigger; ground-level ozone peaks in summer afternoons
Air conditioning: Moulds in AC units, sudden cold air exposure trigger bronchospasm. Advise AC maintenance every 3 months

Biological Triggers

Cockroach allergen: High seroprevalence in Gulf urban areas. Key sensitiser, especially in children. Pest control + sealed food storage
Camel dander: Significant allergen for farm workers, veterinarians, rural families. Test for camel-specific IgE
Date palm pollen: Seasonal peaks February–April across GCC — cross-reactivity with other tree pollens
Indoor mould: High humidity coastal areas (Bahrain, Kuwait coast, Jeddah) in summer

GCC asthma prevalence: Qatar and UAE report up to 13% in adults; Kuwait among highest globally. Sandstorm emergency admissions can triple during haboob events.

🚬 COPD in the GCC Region

Smoking Burden

Male smoking rates: Saudi Arabia ~21%, Kuwait ~26%, Yemen ~28% (highest GCC)
Shisha (waterpipe) smoking: Cultural practice across all GCC countries

Shisha Equivalence: 1 hour of waterpipe smoking = inhalation of 100–200 cigarettes equivalent in terms of smoke volume and carbon monoxide exposure. Many patients do NOT consider shisha as harmful as cigarettes — educate explicitly.

Key Educational Points for Patients

Shisha cafes are COPD risk environments even for non-smokers (passive exposure)
Electronic cigarettes / vaping: not proven safe for lungs; EVALI (e-cigarette associated lung injury) reported in GCC
Saudi Arabia and UAE tobacco regulations: smoke-free public places — important for patient advocacy
National quitlines: Saudi Tobacco Cessation Centre (0800 244 0001)

Underdiagnosis

COPD widely underdiagnosed in GCC — many patients present late (GOLD 3–4)
Spirometry often not performed in primary care — nurse advocates for early testing in smokers >40 years

🌎 Occupational Lung Disease

Silicosis

High-risk workers: construction, sandblasting, stone cutting, glass manufacturing
GCC construction boom → large migrant worker population at risk
Types: acute (intense exposure, months), accelerated (1–10 years), chronic (>10 years)
CXR: upper lobe nodules ± progressive massive fibrosis (PMF)
No specific treatment — silica exposure cessation essential
Increases TB risk 3-fold — annual TST/IGRA screening

Other Occupational Exposures

Cement dust: Chronic bronchitis, COPD, occupational asthma — widespread in GCC construction
Oil and gas workers: H2S, hydrocarbon vapours, benzene — acute and chronic lung toxicity
Agricultural workers: Pesticides, organic dusts — hypersensitivity pneumonitis
Occupational history essential in all respiratory patients

Nurse Role

Occupational history at every new patient assessment
Report to occupational health if exposure ongoing
Advocate for PPE — N95 respiratory protection

🏥 Leading Chest Hospitals in the GCC

Country	Hospital	Notes
Qatar	Hamad Chest Hospital (HCH), Doha	Regional tertiary referral centre; pulmonary hypertension, transplant evaluation
UAE	Rashid Hospital — Chest & Respiratory Unit, Dubai	Major trauma and respiratory centre, ECMO programme
Saudi Arabia	King Fahad Chest Hospital, Riyadh	National referral centre for complex pulmonary disease and thoracic surgery
Saudi Arabia	King Faisal Specialist Hospital, Riyadh/Jeddah	Lung transplantation programme
Kuwait	Chest Diseases Hospital, Shuwaikh	National TB programme, COPD services
Bahrain	Salmaniya Medical Complex — Respiratory Unit	Main tertiary chest service in Bahrain
Oman	Royal Hospital, Muscat — Pulmonology	Sleep medicine, ILD, bronchoscopy services

☾️ Ramadan and Inhaler Use

A common concern for Muslim patients: does using an inhaler break the fast?

Scholarly consensus (majority opinion): Inhaled medications (MDI, DPI, nebuliser) are permitted during Ramadan fasting. The particles are too small to constitute eating/drinking and reach the lungs — not the stomach. This view is supported by the Islamic Fiqh Academy and most GCC religious authorities.

Practical Nursing Guidance

Reassure patients emphatically — skipping inhalers during Ramadan is dangerous and unnecessary
Adjust dosing timing: once-daily inhalers at Iftar (sunset meal) or Suhoor (pre-dawn)
Twice-daily inhalers: Iftar and Suhoor
Patients with brittle asthma or severe COPD: additional monitoring during Ramadan
Nebuliser: permitted (no food substance inhaled)
IV medications, oral steroids, and syrups DO break the fast — seek individual religious guidance for these if medically critical
Provide written information in Arabic if available

Dehydration during Ramadan fasting can increase sputum viscosity in COPD and bronchiectasis. Advise adequate fluid intake at Iftar and Suhoor.

📊 Air Quality and Respiratory Emergency Preparedness

Desert Dust Storm Protocol (Nurse Guidance)

Monitor national AQI alerts (AirVisual, national meteorological apps)
Alert high-risk patients (COPD GOLD 3–4, severe asthma, IPF) in advance via phone
Ensure emergency inhaler/nebuliser supply adequate
Prepare for ED surge: nebuliser bays, oral steroid supply, ABG readiness
Educate: stay indoors, seal windows, avoid outdoor exercise
N95 masks if outdoor exposure unavoidable (standard surgical masks insufficient for PM2.5)

During major dust events, AQI can reach 500+ (Hazardous category). SpO2 monitoring at home with pulse oximeter recommended for high-risk patients.

📊 Spirometry Interpretation

Pattern Recognition

💉 Reversibility Test (Bronchodilator Response)

💥 DLCO (Diffusion Capacity)

🏃 6-Minute Walk Test (6MWT)

Methodology

Clinical Significance

📃 Peak Flow Monitoring

Personal Best

Technique Checklist

📄 GOLD Classification (2023 Update)

Airflow Limitation Severity (FEV1% predicted)

💊 Inhaler Device Selection

💉 Drug Classes: LAMA / LABA / ICS

LAMA (Long-Acting Muscarinic Antagonist)

LABA (Long-Acting Beta2 Agonist)

ICS (Inhaled Corticosteroid)

🚨 Acute COPD Exacerbation Management

Step-by-Step Management

Investigations

💀 NIV for Type 2 Respiratory Failure

NIV Settings (Starting Points)

👑 Pulmonary Rehabilitation

📊 COPD Exacerbation Risk Stratifier (GOLD A/B/E)

🌡 GINA Treatment Steps

💊 Add-On Therapies (Step 4–5)

LAMA (Tiotropium 2.5mcg SMI)

Biologic Therapies

📝 Spacer Technique & Cleaning

Technique (for MDI + Spacer)

Cleaning Spacer

📋 Written Asthma Action Plan

🚨 Acute Severe & Life-Threatening Asthma

Emergency Management

📊 Asthma Control Test (ACT)

💧 Pleural Effusion: Transudate vs Exudate

Common Transudate Causes

Common Exudate Causes

💊 Diagnostic Thoracocentesis

Pre-procedure

Samples to Send

💋 Therapeutic Thoracocentesis

🌄 Pneumothorax Types

💉 Pleurodesis Nursing Care

Pre-procedure

Nursing Management Post-Pleurodesis

🔋 Idiopathic Pulmonary Fibrosis (IPF)

Diagnosis

Management

👀 Sarcoidosis

Pulmonary Staging (Scadding)

Extra-Pulmonary Features

Treatment

❤️ Pulmonary Hypertension

WHO Groups

WHO Functional Class

Vasodilator Therapies (Group 1 PAH)

🌔 Bronchiectasis

Airway Clearance Techniques

Infection Surveillance

Azithromycin Prophylaxis

🌞 GCC-Specific Asthma Triggers

Environmental Triggers

Biological Triggers

🚬 COPD in the GCC Region

Smoking Burden

Key Educational Points for Patients

Underdiagnosis

🌎 Occupational Lung Disease

Silicosis

Other Occupational Exposures

Nurse Role

🏥 Leading Chest Hospitals in the GCC

☾️ Ramadan and Inhaler Use

Practical Nursing Guidance

📊 Air Quality and Respiratory Emergency Preparedness

Desert Dust Storm Protocol (Nurse Guidance)